ArticleFrontiers in endocrinology2026
Functional analysis from ex-vivo characterization of LDLR exon 13-15 duplication associated to familial hypercholesterolemia.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial hypercholesterolemia (FH) is an inherited semidominant disorder characterized by high plasma cholesterol levels and increased risk of premature cardiovascular disease. More than 3,000 low-density lipoprotein receptor (LDLR) variants have been identified, most lack functional evidence to determine their pathogenicity. One of them is the exon13_15dup, the most frequent FH-causing variant in Chile. However, its functional impact is poorly understood. Objective: To determine the functional impact of the exon13_15dup variant in the LDLR, in familial hypercholesterolemia patients. Methods: Three heterozygous carriers of an exon 13-15 duplication and five wild type subjects were recruited. The peripheral blood mononuclear cells were isolated and differentiated to macrophages. The LDLR expression levels on the cell membrane were evaluated by flow cytometry, subcellular localization by confocal microscopy and LDL incorporation by LDL-FITC uptake assays. Results: The exon13_15dup variant leads to significantly increased cell-surface LDLR expression and enhanced localization in the endoplasmic reticulum. This results in a reduced capacity for LDL uptake in patient cells, with principal component analysis highlighting distinct differences in LDLR localization compared to wild-type samples. Conclusions: The functional analysis showed that the mutation affects the proper transport and function of LDLR, resulting in a dysfunctional protein that cannot effectively internalize LDL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.